General Updates

To To Date: October 13, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Dividend Payment Update - Intimation regarding disbursement of final dividend for the FY 2025–26 and withholding of dividend in respect of shareholders with incomplete KYC/bank details or invalid, blocked or closed bank accounts Reference: Regulations 30 and 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the applicable SEBI circulars, including the circular dated November 3, 2021, as subsequently amended, and the applicable Master Circulars for Registrars to an Issue and Share Transfer Agents. Dear Sir/Madam, We wish to inform you that the Members of Bal Pharma Limited (“the Company”), at their 39th Annual General Meeting held on Thursday, September 24, 2026, approved a final dividend of ₹1.20 per equity share of ₹10 each for the financial year 2025–26. The Company has deposited the declared dividend amount into its designated bank account within the prescribed timeline and has completed the disbursement of the final dividend on October 9, 2026, to eligible shareholders whose names appeared in the Register of Members or the records of the Depositories as on the record date, i.e., September 17, 2026. The dividend was remitted through electronic modes, including NACH/NECS/direct bank remittance, wherever valid bank account details were available. Shareholders are requested to verify the credit of the final dividend in their respective bank accounts. They are also advised to check their Form 26AS/AIS or the Income Tax e-filing portal, as applicable, for details of tax deducted at source (“TDS”) on the dividend, wherever applicable. Further, the dividend amounts pertaining to shares already transferred to the Investor Education and Protection Fund (“IEPF”) account will be duly transferred to the prescribed IEPF account in accordance with the applicable provisions of the Companies Act, 2013, and the IEPF Rules. The details of such transfers will also be available on the Company's website for the information of the shareholders. Withholding of Dividend: Shareholders Holding Shares in Physical Form The dividend payable to physical shareholders whose mandatory KYC details and/or bank account particulars are incomplete or have not been updated with the Registrar and Transfer Agent (“RTA”) has been withheld in accordance with the applicable SEBI circulars and guidelines. The dividend amounts that could not be disbursed have been deposited into the Company’s bank account designated for this purpose. The amounts remaining unpaid after the expiry of 30 days from the date of declaration of the dividend shall be transferred to the Company’s Unpaid Dividend Account within the statutory period, in accordance with Section 124 of the Companies Act, 2013, and the applicable rules. KYC updation and release of withheld dividend Physical shareholders are requested to update their KYC and bank account details by submitting the applicable forms and supporting documents to the Company's RTA, MUFG Intime India Private Limited (Unit: Bal Pharma Limited). The applicable forms are as follows: Form ISR-1 For Updation KYC details ie PAN, Address, Bank Particulars, Mobile No. Email ID etc alongwith self attested Aadhar card, PAN card copy, Client Master List (CML) if having demat account. (If shares are in joint name, PAN/Aadhar are required for all joint shareholders). Form ISR-2 For banker attestation of Signature along with Original Cancelled Cheque with your name(s) printed thereon or self-attested copy of bank passbook/statement. Form ISR-3 For “ Opt-out the Nomination, if nomination is not required. Form SH-13 For Updation of Nomination. For release of withheld dividend for FY 2025–26 and previous financial years, shareholders are requested to submit Forms ISR-1 and ISR-2, along with the requisite supporting documents, as applicable. The prescribed forms can be downloaded from the RTA's website: https://web.in.mpms.mufg.com/KYC-downloads.html Address for Submission of KYC documents Registrar and Transfer Agent: MUFG Intime India Private Limited (Unit: Bal Pharma Limited) C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400083. Shareholders are requested to mention “Bal Pharma Limited” as the unit while submitting their documents. Email ID for submission of scanned KYC documents: kyc@in.mpms.mufg.com Copy to: investors@balpharma.com Withholding of Dividend: Shareholders Holding Shares in Dematerialised Form Shareholders holding shares in dematerialised form whose dividend could not be credited due to invalid bank account details or bank accounts that are blocked or closed are requested to update their bank account details with their respective Depository Participant (“DP”). Upon updating the bank account details, shareholders are advised to contact their DP and, where necessary, inform the Company and/or the RTA so that the updated particulars can be appropriately reflected in the relevant records and the dividend payment can be processed, subject to applicable procedures. The Company is taking necessary steps to facilitate the release of withheld dividend upon receipt and verification of the requisite KYC and bank account documents from the concerned shareholders. Contact Details for Investor Queries Shareholders requiring any clarification or assistance regarding KYC updation or dividend payments may contact the Company or its RTA using the below details. Contact details Company RTA Email ID ID investors@balpharma.com investor.helpdesk@in.mpms.mufg.com Website www.balpharma.com www.in.mpms.mufg.com This intimation is being provided for the information of the Stock Exchanges and the shareholders. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681